KVISTGAARD, Denmark, July 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of MVA-BN Brachyury in patients with advanced cancer. MVA-BN Brachyury is a novel, active immunotherapy developed using Bavarian Nordic's proprietary validated MVA platform. This immunotherapy is designed to induce a robust immune response against Brachyury, a tumor-associated antigen which is overexpressed in every major solid tumor setting. Brachyury is believed to play a key role in both the metastasis and progression of tumors. Tumors which overexpress Brachyury are believed to be highly resistant to current therapies and are associated with decreased survival rates. Paul Chaplin, President and CEO of Bavarian Nordic said: "Brachyury is an exciting and novel target which in recent years has come to be associated with highly difficult to treat, aggressive tumors, and we are pleased to introduce our newest pipeline candidate into the clinic. These tumors either fail to respond to current cancer treatments, or have metastasized beyond localized therapies. Using our proprietary and specialized immunotherapy platform, we created a drug candidate which can harness the immune system to target Brachyury and may offer a treatment option to those patients with aggressive or late stage disease. We are proud to be working with the NCI to become one of the leaders in this exciting space as Brachyury continues to gain interest with both investigators and drug developers." The study is an open label, Phase 1 trial that will enroll patients with advanced cancer into three cohorts (6 patients per dose cohort) with dose escalation of MVA-BN Brachyury. Additional patients may be enrolled at the maximum tolerated dose. The objective of the study is to determine the safety and tolerability of escalating doses of MVA-BN Brachyury and to evaluate immunologic responses as measured by an increase in Brachyury-specific T cells. Principal Investigator is Christopher R. Heery, M.D., NCI. Full details for the study can be found here: http://clinicaltrials.gov/ct2/show/NCT02179515. Contacts Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43 Seth Lewis, Vice President Investor Relations (US). Phone +1 978 298 5654 About MVA-BN Brachyury Brachyury is a transcription factor that is involved in mesodermal development in the embryo, and involved in epithelial-mesenchymal transition (EMT) in tumor cells, a key step in tumor invasion and metastasis. MVA-BN Brachyury is based on MVA-BN (Modified vaccinia Ankara Bavarian Nordic), which has been clinically tested in more than 7,300 subjects, including cancer patients, and has shown to be well-tolerated and to induce a strong immune response. The product candidate also employs the TRICOM technology (human T cell costimulatory molecules; B7.1, ICAM-1 and LFA-3), which has been extensively studied in both preclinical and clinical studies and have demonstrated their ability to induce robust T-cell activation and provide evidence of clinical benefit. TRICOM is employed in the Company's other active immunotherapy candidates, PROSTVAC and CV-301. MVA-BN Brachyury has been shown to be a good target for active T cell immunotherapy in preclinical models. About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. [HUG#1836111]
Bavarian Nordic Announces First Patient Treated in a Phase
Top 10 Most Recent News Articles
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal
Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...
Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market
Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...
Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact
A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...
Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win
Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...
Continue ReadingTop 5 Most Recently Viewed Articles
Lawsuit Filed Alleging Eye Injury from Ozempic Use
Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....
Continue Reading
C.H. Robinson Prepares for Upcoming Earnings Conference Call
C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...
Continue Reading
PayPal Surges 14% After Exciting Partnership with OpenAI
PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...
Continue Reading
Unlocking the Future of Ridesharing: Uber and Nvidia's Game Changer
Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...
Continue Reading
Exploring the Future of Organic Infant Formula Market Growth
Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...
Continue Reading